索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]谢林涧 李骊华.血管内皮生长因子在心血管疾病中的作用[J].国际心血管病杂志,2019,04:219-222.
点击复制

血管内皮生长因子在心血管疾病中的作用(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2019年04期
页码:
219-222
栏目:
综述
出版日期:
2019-09-27

文章信息/Info

Title:
-
作者:
谢林涧 李骊华
400016 重庆医科大学附属第一医院心血管内科
Author(s):
-
关键词:
血管内皮生长因子;  高血压;  冠状动脉粥样硬化性心脏病;  肺动脉高压;  心力衰竭
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2019.04.008
文献标识码:
-
摘要:
血管内皮生长因子是一种高度特异性的促血管内皮细胞生长因子,通过结合相关受体发挥重要的生理功能,具有诱导内皮细胞迁移和增殖、增加血管通透性、调节血栓形成等重要作用。抑制血管内皮生长因子及其受体可引起多种心血管疾病并发症。该文介绍血管内皮生长因子在高血压、冠状动脉粥样硬化性心脏病、肺动脉高压及心力衰竭等心血管疾病中的作用。
Abstract:
-

参考文献/References

[ 1 ] Di Lisi D, Madonna R, Zito C, et al. Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond[J]. Int J Cardiol, 2017, 227:11-17.
[ 2 ] Schlieve CR, Mojica SG, Holoyda KA, et al. Vascular endothelial growth factor(VEGF)bioavailability regulates angiogenesis and intestinal stem and progenitor cell proliferation during postnatal small intestinal development[J]. PLoS One, 2016, 11(3):e0151396.
[ 3 ] Taimeh Z, Loughran J, Birks EJ, et al. Vascular endothelial growth factor in heart failure[J]. Nat Rev Cardiol, 2013, 10(9):519-530.
[ 4 ] Park SA, Jeong MS, Ha KT, et al. Structure and function of vascular endothelial growth factor and its receptor system[J]. BMB Rep, 2018, 51(2):73-78.
[ 5 ] Lautz T, Lasch M, Borgolte J, et al. Midkine controls arteriogenesis by regulating the bioavailability of vascular endothelial growth factor a and the expression of nitric oxide synthase 1 and 3[J]. EBioMedicine, 2018, 27:237-246.
[ 6 ] Liu B, Ding FX, Liu Y, et al. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients[J]. Oncotarget, 2016, 7(41):67661-67673.
[ 7 ] Gélinas DS, Bernatchez PN, Rollin S, et al. Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways[J]. Br J Pharmacol, 2002, 137(7):1021-1030.
[ 8 ] He H, Venema VJ, Gu X, et al. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src[J]. J Biol Chem, 1999, 274(35):25130-25135.
[ 9 ] Malyszko J, Mayszko M, Kozlowski L, et al. Hypertension in malignancy—an underappreciated problem[J]. Oncotarget, 2018, 9(29):20855-20871.
[10] Amraoui F, Spijkers L, Lahsinoui HH, et al. SFlt-1 elevates blood pressure by augmenting endothelin-1-mediated vasoconstriction in mice[J]. PLoS One, 2014, 9(3):e91897.
[11] Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis[J]. Cell, 2007, 130(4):691-703.
[12] Wada H, Ura S, Kitaoka S, et al. Distinct characteristics of circulating vascular endothelial growth factor-A and C levels in human subjects[J]. PLoS One, 2011, 6(12):e29351.
[13] Amara S, Tiriveedhi V. Inflammatory role of high salt level in tumor microenvironment[J]. Int J Oncol, 2017, 50(5):1477-1481.
[14] Zhao Q, Ishibashi M, Hiasa K, et al. Essential role of vascular endothelial growth factor in angiotensin Ⅱ-induced vascular inflammation and remodeling[J]. Hypertension, 2004, 44(3):264-270.
[15] Marek-Trzonkowska N, Kwieczynska A, Reiwer-Gostomska M, et al. Arterial hypertension is characterized by imbalance of pro-angiogenic versus anti-angiogenic factors[J]. PLoS One, 2015, 10(5):e0126190.
[16] Belgore FM, Blann AD, Li-Saw-Hee FL, et al. Plasma levels of vascular endothelial growth factor and its soluble receptor(SFlt-1)in essential hypertension[J]. Am J Cardiol, 2001, 87(6):805-807.
[17] Eppler SM, Combs DL, Henry TD, et al. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans[J]. Clin Pharmacol Ther, 2002, 72(1):20-32.
[18] Mazidi M, Rezaie P, Kengne AP, et al. VEGF, the underlying factor for metabolic syndrome; fact or fiction?[J]. Diabetes Metab Syndr, 2017, 11(1):61-64.
[19] Escobedo N, Oliver G. the lymphatic vasculature: its role in adipose metabolism and obesity[J]. Cell Metab, 2017, 26(4):598-609.
[20] Blann AD, Belgore FM, Constans J, et al. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate[J]. Am J Cardiol, 2001, 87(10):1160-1163.
[21] Li LF, Liu HY, Xu CX, et al. VEGF promotes endothelial progenitor cell differentiation and vascular repair through connexin 43[J]. Stem Cell Res Ther, 2017, 8(1):237.
[22] Zhang Z, Yao L, Yang J, et al. PI3K/Akt and HIF1 signaling pathway in hypoxia-ischemia[J]. Mol Med Rep, 2018, 18(4):3547-3554.
[23] 杨敏, 刘奇峰, 蓝新平, 等. 急性冠脉综合征患者血清Periostin、VEGF、CRP检测及与心肌损伤的关系[J]. 海南医学院学报, 2015, 21(7):898-900.
[24] Niu J, Han X, Qi H, et al. Correlation between vascular endothelial growth factor and long-term prognosis in patients with acute myocardial infarction[J]. Exp Ther Med, 2016, 12(1):475-479.
[25] Harada K, Kikuchi R, Ishii H, et al. Association between the ratio of anti-angiogenic isoform of VEGF-A to total VEGF-A and adverse clinical outcomes in patients after acute myocardial infarction[J]. Int J Cardiol Heart Vasc, 2018, 19:3-7.
[26] Hartikainen J, Hassinen I, Hedman A, et al. Adenoviral intramyocardial VEGF-DΔNΔC gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase Ⅰ/Ⅱa study with 1-year follow-up[J]. Eur Heart J, 2017, 38(33):2547-2555.
[27] Carlsson L, Clarke JC, Yen CA, et al. Biocompatible, purified VEGF-A mRNA improves cardiac function after intracardiac injection 1 week post-myocardial infarction in swine[J]. Mol Ther Methods Clin Dev, 2018, 9:330-346.
[28] Tuder RM, Chacon M, Alger L, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis[J]. J Pathol, 2001, 195(3):367-374.
[29] 李启芳, 戴爱国. 缺氧诱导因子1α调控血管内皮生长因子对大鼠缺氧性肺动脉高压的作用[J]. 中华结核和呼吸杂志, 2004, 27(3):33-37.
[30] Säleby J, Bouzina H, Lundgren J, et al. Angiogenic and inflammatory biomarkers in the differentiation of pulmonary hypertension[J]. Scand Cardiovasc J, 2017, 51(5):261-270.
[31] Touyz RM, Lang NN, Herrmann J, et al. Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition[J]. Hypertension, 2017, 70(2):220-226.
[32] Duan QL, Ni L, Wang PH, et al. Deregulation of XBP1 expression contributes to myocardial vascular endothelial growth factor-A expression and angiogenesis during cardiac hypertrophy in vivo[J]. Aging Cell, 2016, 15(4):625-633.
[33] Wang B, Yang Q, Bai WW, et al. Tongxinluo protects against pressure overload-induced heart failure in mice involving VEGF/Akt/eNOS pathway activation[J]. PLoS One, 2014, 9(6):e98047.

备注/Memo

备注/Memo:
基金项目:重庆市卫生局资助项目(2016MSXM009); 国家临床重点专科建设资助项目(财社[2011]170号)
作者单位:400016 重庆医科大学附属第一医院心血管内科
通信作者:李骊华,Email:lilihua926@163.com
更新日期/Last Update: 2019-09-27